{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:30:12Z","timestamp":1794432612185,"version":"4.9.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Pfizer, Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.schres.2011.07.028","type":"journal-article","created":{"date-parts":[[2011,8,29]],"date-time":"2011-08-29T22:47:33Z","timestamp":1314658053000},"page":"108-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Placebo response trajectories in short-term and long-term antipsychotic trials in schizophrenia"],"prefix":"10.1016","volume":"132","author":[{"given":"Steven","family":"Potkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Agid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Watsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Vanderburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2011.07.028_bb0005","series-title":"APA Annual Meeting, New Orleans, May 2010","article-title":"Meta-analysis of placebo response in antipsychotic trials","author":"Agid","year":"2010"},{"issue":"2","key":"10.1016\/j.schres.2011.07.028_bb0010","first-page":"159","article-title":"The Negative Symptom Assessment: a new instrument to assess negative symptoms of schizophrenia","volume":"25","author":"Alphs","year":"1989","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.schres.2011.07.028_bb0105","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987"},{"key":"10.1016\/j.schres.2011.07.028_bb0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"The Ziprasidone Extended Use in Schizophrenia (ZEUS) study: a double-blind, placebo-controlled, 1-year clinical trial","volume":"17","author":"Arato","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.07.028_bb0020","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1176\/ajp.145.5.578","article-title":"Deficit and nondeficit forms of schizophrenia: the concept","volume":"145","author":"Carpenter","year":"1988","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.07.028_bb0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/pst.439","article-title":"Trial design issues and treatment effect modeling in multi-regional schizophrenia trials","volume":"9","author":"Chen","year":"2010","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.schres.2011.07.028_bb0030","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80mg\/day and 160mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2011.07.028_bb0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/schbul\/sbn094","article-title":"Negative symptoms in schizophrenia: avolition and Occam's razor","volume":"36","author":"Foussias","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.07.028_bb0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/S0007125000291514","article-title":"The Positive and Negative Syndrome Scale (PANSS): rationale and standardization","volume":"155","author":"Kay","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.07.028_bb0045","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/schbul\/sbn110","article-title":"What is causing the reduced drug\u2013placebo difference in recent schizophrenia clinical trials and what can be done about it?","volume":"36","author":"Kemp","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.07.028_bb0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.07.028_bb0055","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(94)90515-0","article-title":"Placebo effects in psychiatry","volume":"344","author":"Laporte","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2011.07.028_bb0060","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0006-3223(99)00321-2","article-title":"The use of placebo control groups in the assessment of psychiatric drugs: an historical context","volume":"47","author":"Leber","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2011.07.028_bb0065","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/schbul\/sbn120","article-title":"Trajectories and antecedents of treatment response over time in early-episode psychosis","volume":"36","author":"Levine","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.07.028_bb0070","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.biopsych.2010.01.012","article-title":"Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories","volume":"68","author":"Levine","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2011.07.028_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbq161","article-title":"Methodological issues in negative symptom trials","author":"Marder","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.07.028_bb0080","article-title":"The different trajectories of antipsychotic response: antipsychotics versus placebo","author":"Marques","year":"2010","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2011.07.028_bb0085","series-title":"Mplus: Statistical Analysis with Latent Variables: User's Guide","author":"Muthen","year":"2008"},{"key":"10.1016\/j.schres.2011.07.028_bb0090","series-title":"ECDEU Assessment Manual for Psychopharmacology","article-title":"Clinical Global Impression Improvement Scale","author":"National Institutes of Mental Health","year":"1976"},{"key":"10.1016\/j.schres.2011.07.028_bb0095","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/JCP.0b013e3181e69042","article-title":"A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial","volume":"30","author":"Stahl","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.07.028_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-002-1299-4","article-title":"Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression","volume":"166","author":"Welge","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2011.07.028_bb0110","series-title":"Ziprasidone, package insert","year":"2010"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996411004269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996411004269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:23:29Z","timestamp":1760297009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996411004269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":22,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0920996411004269"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2011.07.028","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placebo response trajectories in short-term and long-term antipsychotic trials in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2011.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}